ICI 142269: RN given refers to (Z)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3033897 |
| CHEMBL ID | 46128 |
| SCHEMBL ID | 4620164 |
| MeSH ID | M0149323 |
| Synonym |
|---|
| ici 142269 |
| CHEMBL46128 |
| 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]ethanol |
| 77207-49-9 |
| ici-142269 |
| deamino-hydroxytamoxifen |
| ethanol, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-, (z)- |
| tamoxifen metabolite y |
| tamoxifen-ol |
| SCHEMBL4620164 |
| Q32039328 |
| (z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)ethan-1-ol |
| DTXSID701219780 |
| 2-[4-[(1z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethanol |
| ethanol, 2-[4-[(1z)-1,2-diphenyl-1-buten-1-yl]phenoxy]- |
| F74719 |
| AKOS040751446 |
| Pathway | Proteins | Compounds |
|---|---|---|
| Tamoxifen metabolism | 0 | 13 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID69397 | Displacement of [3H]estradiol from estrogen receptor in rat uterine cytosol | 1982 | Journal of medicinal chemistry, Feb, Volume: 25, Issue:2 | Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basici |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||